When does the carfilzomib patent expire?
The exact “patent expiration date” for carfilzomib depends on which specific patent (or patent family) you mean, because drug products usually have multiple patents covering different aspects (the molecule, formulations, methods of use, and manufacturing). Carfilzomib’s market exclusivity timeline also depends on the country (for example, the US vs. EU vs. UK).
No patent-expiration dates were provided in the information available to me here, so I can’t state a definitive expiration date without a specific patent number, jurisdiction, or source list to anchor the dates.
What patents control carfilzomib’s market exclusivity (and why the date can differ)?
For oncology drugs like carfilzomib, the effective “can generics/biosimilars launch?” timing is often determined by a mix of:
- Compound/method-of-use patents (molecule claims and clinical use claims)
- Formulation/manufacturing patents (how the drug is made or presented)
- Regulatory exclusivities (not strictly “patent expiration,” but can delay approval/marketing even after patents end)
Because these differ by jurisdiction, two people can cite different “expiration dates” and both be referencing different legal protections.
How do I find the correct expiration date quickly (what to look up)?
To pin down the expiration date accurately, you typically need:
- Jurisdiction: US, EP (European patent), UK, etc.
- Patent identifier: patent number or application/publication number
- Patent family: which member governs the region where you care about launch timing
- Whether you want legal expiration (last day the patent is in force) vs. regulatory exclusivity end (which can be later)
If you tell me the country (e.g., “US”) and either a patent number or the brand/product name and manufacturer you’re tracking, I can help you identify which patents usually control the timeline and what “expiration date” means in that context.
Can biosimilars or generics launch right after the last patent expires?
Not always. Even after patent expiry, companies may still face:
- Remaining patents in the same family or related families (other claims that extend timelines)
- Regulatory exclusivity rules that can bar or limit marketing/approval paths for a period after some patents expire
- Litigation that can delay launch even when a patent is nearing or past expiration
So the “last patent expiration date” is only one part of the entry timing.
Tell me what you need and I’ll narrow it down
Reply with:
1) Which country (US / EU / UK / other)?
2) Whether you mean patents listed for the molecule, a specific formulation, or a specific use.
3) Any patent number(s) you already have (optional).
With that, I can give you the correct expiration date(s) for the relevant carfilzomib patents instead of a potentially wrong single date.